Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies.

Jyseleca (filgotinib) - Gilead

http://www.ncbi.nlm.nih.gov/pubmed/42536126

Carole Van der Donckt; Gerd R Burmester; James Galloway; Jerome Avouac; Karen Bevers; Neil Betteridge; Ouafia Tandjaoui Bouzid; Patrick Verschueren; Roberto F Caporali; Susana Romero-Yuste; Thomas P A Debray

Aug 1, 2026